Literature DB >> 11140379

Structural basis of Wiskott-Aldrich syndrome causing mutations in the WH1 domain.

S B Rong1, M Vihinen.   

Abstract

Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency disease associated with eczema, hemorrhagic episodes, and recurrent severe infections. The N-terminus of the cytoplasmic WAS protein (WASP) has similarity to WH1 domains, which recognize proline-rich sequences and direct protein localization and formation of multicomponent assemblies. About one-half of the WAS-causing mutations affect the WH1 domain, but this forms only about one-fifth of the length of the protein. To understand the structural and functional effects of WAS-causing mutations within the WH1 domain, the three-dimensional model of the WASP WH1 domain was constructed based on the crystal structures of the Mena and Ev1 EVH1 (WH1) domains. Based on the model, the protein structural effects of the mutations were evaluated and putative ligand-binding regions identified. Mutations in the WASP WH1 domain were found to influence both the function and structure of the WASP. The amino acid substitutions cause general and local structural changes because of steric clashes and changes to the positions of adjacent strands and the fold of the protein. Some mutations alter the electrostatics and interactions with partners and other domains of WASP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140379     DOI: 10.1007/s001090000136

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  9 in total

1.  WASP-interacting protein is important for actin filament elongation and prompt pseudopod formation in response to a dynamic chemoattractant gradient.

Authors:  Scott A Myers; Laura R Leeper; Chang Y Chung
Journal:  Mol Biol Cell       Date:  2006-08-09       Impact factor: 4.138

2.  Disease-associated missense mutations in the EVH1 domain disrupt intrinsic WASp function causing dysregulated actin dynamics and impaired dendritic cell migration.

Authors:  Austen J J Worth; Joao Metelo; Gerben Bouma; Dale Moulding; Marco Fritzsche; Bertrand Vernay; Guillaume Charras; Giles O C Cory; Adrian J Thrasher; Siobhan O Burns
Journal:  Blood       Date:  2012-11-15       Impact factor: 22.113

3.  Functional roles of VASP phosphorylation in the regulation of chemotaxis and osmotic stress response.

Authors:  Wan-Hsin Lin; Sharon E Nelson; Ryan J Hollingsworth; Chang Y Chung
Journal:  Cytoskeleton (Hoboken)       Date:  2010-04

4.  A neural-specific splicing event generates an active form of the Wiskott-Aldrich syndrome protein.

Authors:  Yann Le Page; Florence Demay; Gilles Salbert
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

5.  Interaction of the endocytic scaffold protein Pan1 with the type I myosins contributes to the late stages of endocytosis.

Authors:  Sarah L Barker; Linda Lee; B Daniel Pierce; Lymarie Maldonado-Báez; David G Drubin; Beverly Wendland
Journal:  Mol Biol Cell       Date:  2007-05-23       Impact factor: 4.138

6.  Clinical and molecular characteristics of 35 Chinese children with Wiskott-Aldrich syndrome.

Authors:  Pamela P W Lee; Tong-Xin Chen; Li-Ping Jiang; Jing Chen; Koon-Wing Chan; Tze-Leung Lee; Marco H K Ho; Shao-Han Nong; Yin Yang; Yong-Jun Fang; Qiang Li; Xiao-Chun Wang; Xi-Qiang Yang; Yu-Lung Lau
Journal:  J Clin Immunol       Date:  2009-03-24       Impact factor: 8.317

7.  Stoichiometry of Nck-dependent actin polymerization in living cells.

Authors:  Jonathon A Ditlev; Paul J Michalski; Greg Huber; Gonzalo M Rivera; William A Mohler; Leslie M Loew; Bruce J Mayer
Journal:  J Cell Biol       Date:  2012-05-21       Impact factor: 10.539

8.  Spectrum of disease-causing mutations in protein secondary structures.

Authors:  Sofia Khan; Mauno Vihinen
Journal:  BMC Struct Biol       Date:  2007-08-29

9.  The intersectin 2 adaptor links Wiskott Aldrich Syndrome protein (WASp)-mediated actin polymerization to T cell antigen receptor endocytosis.

Authors:  M K McGavin; K Badour; L A Hardy; T J Kubiseski; J Zhang; K A Siminovitch
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.